Morgan Stanley lowered the firm’s price target on Genmab (GMAB) to $33 from $34 and keeps an Equal Weight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab: Buy Rating Reiterated as 2026 Pivotal Data Catalysts and Strong Epkinly Momentum Make 15% Share Pullback an Attractive Entry Point
- Genmab reports Q1 operating profit $180M, consensus $172.7M
- Genmab maintains FY26 guidance
- Genmab Advances Rina S Into Phase 2 GI Cancer Trial, Raising Long Term Pipeline Hopes
- Genmab Posts Strong Q1 2026 Revenue Growth and Highlights FDA Label Change for EPKINLY